[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633984":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":11,"centralContacts":49,"locations":55,"responsibleParty":87,"collaborators":11,"id":89,"slug":11,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":11,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":11,"enrollmentInfo":97,"targetDuration":11,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":11,"overallStatus":58,"whyStopped":11,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Haisco Pharmaceutical Group Co., Ltd.","INDUSTRY",[8,14,18,22,27],{"label":9,"type":10,"description":11,"interventionNames":12},"HSK55718 dose level1","EXPERIMENTAL",null,[13],"Drug: HSK55718 dose level1",{"label":15,"type":10,"description":11,"interventionNames":16},"HSK55718 dose level2",[17],"Drug: HSK55718 dose level2",{"label":19,"type":10,"description":11,"interventionNames":20},"HSK55718 dose level 3",[21],"Drug: HSK55718 dose level 3",{"label":23,"type":24,"description":11,"interventionNames":25},"Placebo control","PLACEBO_COMPARATOR",[26],"Drug: Placebo control",{"label":28,"type":29,"description":11,"interventionNames":30},"morphine","ACTIVE_COMPARATOR",[31],"Drug: morphine",[33,37,40,43,46],{"type":34,"name":9,"description":35,"armGroupLabels":36,"otherNames":11},"DRUG","Patients administrated with HSK55718 at dose level 1",[9],{"type":34,"name":15,"description":38,"armGroupLabels":39,"otherNames":11},"Patients administrated with HSK55718 at dose level 2",[15],{"type":34,"name":19,"description":41,"armGroupLabels":42,"otherNames":11},"Patients administrated with HSK55718 at dose level 3",[19],{"type":34,"name":23,"description":44,"armGroupLabels":45,"otherNames":11},"Patients administrated with placebo",[23],{"type":34,"name":28,"description":47,"armGroupLabels":48,"otherNames":11},"Patients administrated with morphine",[28],[50],{"name":51,"role":52,"phone":53,"phoneExt":11,"email":54},"Yongrui Wang","CONTACT","028-67258779","wangyr@haisco.com",[56,73],{"facility":57,"status":58,"city":59,"state":60,"zip":11,"country":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"The Third Xiangya Hospital of Central South University","RECRUITING","Changsha","Hunan","China",{"type":63,"coordinates":64},"Point",[65,66],112.97087,28.19874,{"lat":66,"lon":65},[69],{"name":70,"role":52,"phone":71,"phoneExt":11,"email":72},"Saiying Wang","0731-88618150","1771303488@qq.com",{"facility":74,"status":58,"city":75,"state":76,"zip":11,"country":61,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Sichuan Provincial People's Hospital","Chengdu","Sichuan",{"type":63,"coordinates":78},[79,80],104.06667,30.66667,{"lat":80,"lon":79},[83],{"name":84,"role":52,"phone":85,"phoneExt":11,"email":86},"Mengchang Yang","028-87393632","ymc681@126.com",{"type":88,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100633984",false,"NCT07533786","A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery","A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK55718 Injection for Postoperative Pain Treatment in Abdominal Surgery","Inclusion Criteria:\n\n* Age ≥18 years old, regardless of gender;\n* 18 kg\u002Fm2≤BMI≤30 kg\u002Fm2;\n* American Society of Anesthesiologists (ASA) gradeⅰ-ⅲ;\n* Accept abdominal surgery under general anesthesia;\n* Within 4 hours after the end of surgery, NRS≥4 in the resting state at any time;\n* Fully understand and voluntarily participate this trial, and sign the informed consent form;\n\nExclusion Criteria:\n\n* A history of cardiovascular, respiratory, neurological, or psychiatric diseases that meet the protocol-defined exclusion criteria.\n* Clinically significant abnormalities in laboratory tests during the screening period.\n* A history of severe drug allergy or known allergy to the investigational drug.\n* Continuous use of opioid analgesics for more than 10 days for any reason within 3 months prior to randomization.\n* Use of any medication that may affect analgesia, where the last dose was administered less than 5 half-lives of that drug before randomization.\n* A history of drug abuse, substance abuse, and\u002For alcohol abuse within the past year.\n* Pregnant or lactating women.\n* Participation in another drug clinical trial within 3 months prior to the screening period.\n* Presence of any sensory dysfunction.\n* Presence of any painful physical condition.\n* Subjects with any other factor considered by the investigator to be ineligible for participation in the trial.","ALL","18 Years",{"count":98,"type":99},200,"ESTIMATED","INTERVENTIONAL",[102],"PHASE2","This is a multi-center, randomized, double-blind, double-dummy, placebo\u002Factive-controlled study. 200 subjects undergoing abdominal surgery under general anesthesia are planned to be enrolled and randomized into the HSK55718 group, morphine group, and placebo group.",[105],"Pain After Surgery","2026-05-24",{"date":108,"type":109},"2026-05-28","ACTUAL",{"date":111,"type":109},"2026-05-22",{"date":113,"type":99},"2026-11-22",{"name":5,"class":6},2]